Listed pet care firms post modest gains, but resilience stands out

Version 2

Publicly listed pet care companies are delivering steady, if unspectacular, returns, and that may be the bigger story for the veterinary industry right now. GlobalPETS reported that the Global Pet Care Index generated a 3.16% gross return over the past 12 months, framing the sector as resilient even as companies face elevated costs, slower growth than in the pandemic-era boom, and uneven investor sentiment. The market signal is less about breakout performance than about durability. (petfoodindustry.com)

That resilience has been building for a while. Coverage of public pet companies in 2025 showed growth moderating from earlier highs, but earnings recovering as businesses focused more aggressively on efficiency, mix, and margin. Cascadia Capital’s pet industry overview, as cited by PetfoodIndustry, found revenue for its index of publicly traded pet companies rose 6.9% year over year in 2024, up from 1.9% in 2023, while analysts said investor attention had shifted toward profitability over pure growth. In other words, the market has become more selective, but not necessarily less interested in pet care. (petfoodindustry.com)

Recent company results help explain why. GlobalPETS’ reporting on pet food and retail results showed a split market: Chewy grew second-quarter FY2025 net sales 8.6% to $3.1 billion, with autoship sales accounting for 83% of revenue, while Musti and Pet Valu also posted gains. At the same time, Central Garden & Pet reported softer demand in durable pet products, and Petco’s sales slipped even as operating income improved. In food and nutrition, Freshpet posted double-digit sales growth, while Nestlé’s Purina business remained large and stable but grew more slowly, reflecting a broader category slowdown. (globalpetindustry.com)

H&H Group offers a useful case study in where growth is still happening. Its 2024 annual report said Zesty Paws and Solid Gold were present in more than 18,000 and 4,800 US stores, respectively, by the end of 2024, while the company was reallocating resources toward higher-margin pet food and supplement products. In the first half of 2025, H&H reported its Pet Nutrition and Care segment grew 8.6%, with high-margin pet food and supplements making up 33.8% of segment revenue in mainland China. GlobalPETS later reported third-quarter pet segment revenue of RMB 510.8 million and said FY2025 pet revenue reached RMB 2.5 billion, with Zesty Paws as the main driver. Even so, margin pressure persisted, a reminder that growth alone isn’t solving every challenge in the category. (www1.hkexnews.hk)

Industry commentary points in a similar direction. PetfoodIndustry, citing Cascadia Capital, said top-line growth has moderated after pandemic highs, but earnings per share have continued to recover because of operational efficiencies. GlobalPETS’ broader market snapshots also suggest premium and health-led products are holding up better than lower-priority purchases. That aligns with H&H’s own strategy, which emphasizes supplements and premium nutrition, and with retailer results showing stronger performance in recurring or routine spending models. (petfoodindustry.com)

Why it matters: For veterinary professionals, this is a business story with clinical relevance. When public pet companies outperform through supplements, premium nutrition, subscription purchasing, and veterinary-linked services, it suggests pet parents are still prioritizing products and care they see as essential to health, even when discretionary spending is under pressure. That could support continued demand for preventive care, therapeutic nutrition, parasite prevention, and other medically adjacent categories sold through or recommended by veterinary teams. At the same time, margin pressure across the sector means manufacturers and retailers may keep tightening assortments, pushing premium products, and looking for more efficient channels, which can affect pricing, availability, and partnership opportunities in clinics. (hkexnews.hk)

Another implication is that resilience in pet care isn’t evenly distributed. Veterinary services and health-oriented categories appear more defensive than accessories, hardgoods, or weaker digital channels. Pets at Home’s 7.1% growth in veterinary revenue despite broader softness is one of the clearest examples from recent reporting. For practices, that may reinforce the value of leaning into wellness plans, continuity of care, nutrition guidance, and trusted product recommendations that meet pet parent demand for practical, health-centered spending. (globalpetindustry.com)

What to watch: The next round of earnings will show whether modest stock returns turn into stronger momentum, or whether the sector remains a relative safe harbor defined by selective growth, premiumization, and careful cost control. Key markers will include margin recovery, supplement category performance, recurring revenue trends, and whether veterinary and health-focused segments continue to outpace the rest of pet care. (investing.com)